CANF Company Profile and Key Details

Q: Who are the executives of CANF?

Dr. Vibeke Strand FACP, FACR, FACR (USA), M.D.Senior Clinical AdvisorDr. Sari Fishman Ph.D.Vice President of Bus. Devel.Dr. Pnina Fishman Ph.D.Founder, Chief Scientific Officer & Executive ChairmanDr. Vibeke S. Strand FACP, FACR, FACR (USA), M.D.Senior Clinical AdvisorMr. Motti FarbsteinChief Executive Officer & Chief Operating and Financial OfficerDr. Ilan Cohn Ph.D.Co-Founder & Director

AMEX : CANF

Can-Fite BioPharma

$4.25

0.21+5.20%

At Close 4:00 PM

66.28

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Can-Fite BioPharma Ltd. (CANF) stock surged +5.20%, trading at $4.25 on AMEX, up from the previous close of $4.04. The stock opened at $4.10, fluctuating between $4.10 and $4.46 in the recent session.

Stock Snapshot

4.04

Prev. Close

2.29M

Market Cap

4.1

Day Low

-1.63

P/E Ratio

-2.6

EPS (TTM)

0.02

Cash Flow per Share

4.1

Open

538K

Number of Shares

4.46

Day High

27,304.3%

Free Float in %

1.38

Book Value

513.23K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 05, 2026	4.10	4.50	4.10	4.25	521.92K
Feb 04, 2026	4.25	4.27	4.04	4.04	16.43K
Feb 03, 2026	4.13	4.17	4.00	4.05	21.54K
Feb 02, 2026	4.16	4.32	4.05	4.13	23.55K
Jan 30, 2026	4.00	4.18	4.00	4.01	18.97K
Jan 29, 2026	4.37	4.55	4.10	4.10	24.19K
Jan 28, 2026	4.53	4.53	4.35	4.43	15.68K
Jan 27, 2026	4.38	4.64	4.34	4.47	42.22K
Jan 26, 2026	4.47	4.60	4.32	4.34	50.44K
Jan 23, 2026	4.23	4.60	4.17	4.47	72.51K
Jan 22, 2026	4.08	4.39	3.98	4.16	94.96K
Jan 21, 2026	4.02	4.15	3.91	4.08	58.59K
Jan 20, 2026	4.10	4.17	3.87	3.99	231.14K
Jan 02, 2026	76.00	88.00	74.40	88.00	6.7K
Dec 31, 2025	73.88	80.92	71.52	80.00	8.41K
Dec 30, 2025	68.60	79.88	67.60	73.40	10.4K
Dec 29, 2025	79.04	84.00	67.12	68.60	14.51K
Dec 26, 2025	108.28	109.40	84.00	85.56	435.69K
Dec 24, 2025	80.00	80.92	68.00	72.12	9.45K
Dec 23, 2025	100.40	100.40	93.36	96.20	1.62K

Contact Details

Petah Tikva, 4951778

Israel

https://www.canfite.com 972 392 41114

About Company

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Stock Peers

TBXU

-0.2104-0.60%

Direxion Shares ETF Trust$35.11 PTN

0.13+0.82%

Palatin Technologies, Inc.$16.05 AGE

-1.5-11.90%

AgeX Therapeutics, Inc.$11.10 CYBN

0.1+1.22%

Cybin Inc.$8.28 ARMP

-0.02-0.25%

Armata Pharmaceuticals, Inc.$8.08 NSRX

-0.25-4.31%

Nasus Pharma Ltd.$5.55 CVM

-0.11-2.20%

CEL-SCI Corporation$4.90 PHGE

-0.73-13.80%

BiomX Inc.$4.56 PLX

0.01+0.34%

Protalix BioTherapeutics, Inc.$2.91 MAIA

-0.23-10.75%

MAIA Biotechnology, Inc.$1.91

Frequently Asked Questions

What is the current Can-Fite BioPharma Ltd. (CANF) stock price?

Can-Fite BioPharma Ltd. (AMEX: CANF) stock price is $4.25 in the last trading session. During the trading session, CANF stock reached the peak price of $4.46 while $4.10 was the lowest point it dropped to. The percentage change in CANF stock occurred in the recent session was 5.2% while the dollar amount for the price change in CANF stock was $0.21.

CANF's industry and sector of operation?

The AMEX listed CANF is part of Biotechnology industry that operates in the broader Healthcare sector. Can-Fite BioPharma Ltd. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CANF?

Dr. Vibeke Strand FACP, FACR, FACR (USA), M.D.
Senior Clinical Advisor
Dr. Sari Fishman Ph.D.
Vice President of Bus. Devel.
Dr. Pnina Fishman Ph.D.
Founder, Chief Scientific Officer & Executive Chairman
Dr. Vibeke S. Strand FACP, FACR, FACR (USA), M.D.
Senior Clinical Advisor
Mr. Motti Farbstein
Chief Executive Officer & Chief Operating and Financial Officer
Dr. Ilan Cohn Ph.D.
Co-Founder & Director

How CANF did perform over past 52-week?

CANF's closing price is 25% higher than its 52-week low of $3.40 where as its distance from 52-week high of $46.60 is -90.88%.

How many employees does CANF have?

Number of CANF employees currently stands at 5.

Link for CANF official website?

Official Website of CANF is: https://www.canfite.com

How do I contact CANF?

CANF could be contacted at phone 972 392 41114 and can also be accessed through its website. CANF operates from 10 Bareket Street, Petah Tikva, 4951778, Israel.

How many shares of CANF are traded daily?

CANF stock volume for the day was 513.23K shares. The average number of CANF shares traded daily for last 3 months was 519.47K.

What is the market cap of CANF currently?

The market value of CANF currently stands at $2.29M with its latest stock price at $4.25 and 538K of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	5
Beta	0.04
Sales or Revenue	$743.00K
5Y Sales Change%	-0.994%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	5
Beta	0.04
Sales or Revenue	$743.00K
5Y Sales Change%	-0.994%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CANF Company Profile and Key Details

Can-Fite BioPharma

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Shareholding & Insider Activity

Technical Performance

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook